• New York health regulators say Tiger Medical smuggled alloClae into the state and lied about it.
• A court filing includes photos of boxes piled in the driveway of a New Jersey nurse who regulators allege drove the product to NYC.
• Tiger says only the FDA, not New York State, can regulate alloClae, and denied wrongdoing.

On a blustery December day, nine large white cardboard boxes sat stacked next to a garbage can in the driveway of a New Jersey nurse as a man packed them into the bed of a pickup truck.

Other than a manufacturer's label in the corner and a note that the contents were perishable and shouldn't be frozen, there was no indication they held thousands of dollars' worth of processed cadaver fat. Inside the boxes, state regulators allege, was alloClae, a hot new injectable filler derived from the fat of dead people and headed to high-end cosmetic surgeon practices in New York City.

Photos of the boxes were part of a recent court filing by New York State health officials, who have accused Tiger Medical Holdings, which manufactures and sells alloClae with its affiliates, of "smuggling" the product into New York.

Tiger has said only the Food and Drug Administration has the authority to regulate alloClae, and that FDA rules don't require premarket approval. New York is one of a handful of states that issues permission to store and distribute human tissue, and it claims that Tiger violated those rules by bringing alloClae to market without waiting for approval.

Recent court filings reveal that the state obtained FedEx records, including photos, in an attempt to prove that Tiger organized a scheme to smuggle hundreds of boxes of the product — possibly over $1 million worth — into New York.

The dispute could affect the availability of a product that lets busy C-suiters get a boob job during a lunch break or a butt lift between meetings. Doctors have said the injectable is flying off the shelves, and some have continued to administer it during the state investigation.

Tiger co-CEO Oliver Burckhardt said in a filing on Wednesday that 60 doctors have contacted the company about the fat spat with New York — some worried about the case, but most wanting to buy more alloClae.

Tiger hasn't disputed shipping alloClae through New Jersey, though it has called the state's evidence "unreliable" and "self-serving," and said the allegation of "smuggling" is baseless and inflammatory.

It said the health department kept asking for more information without signaling concerns until last month, and that the company submitted testing data as recently as January to show that alloClae was safe.

Tiger's lawyer, Larry Wood Jr., did not address specific questions from Business Insider, referring a reporter to Tiger's court filings.

Building buzz for alloClae while dealing with regulators

AlloClae hit the market in 2024. It didn't take long for plastic surgeons on Manhattan's Tribeca and Upper East Side to realize the appeal. Their patients wanted a quick touch-up and were willing to pay for the convenience. In small quantities, the product can be injected for under $10,000; in other cases, it can cost up to $100,000 per procedure.

The product is a good fit for "the CEOs, COOs, CCOs that don't want to be away from the boardroom," Douglas Steinbrech, who practices in New York City, Beverly Hills, and Chicago, told Business Insider last year. "They have to go to a lot of meetings that just pop up, and they cannot control when they're going to happen. They can't just clear their schedule to recover for a surgery."

AlloClae was advertised on social media and websites: "Revolutionary," said one clinic. "Pure Gold. On Demand," said another.

In a video posted by a Texas plastic surgery practice, audio of Oprah gifting cars to a screaming audience was dubbed over a man in scrubs pretending to dole out alloClae boxes to employees who wriggled with excitement.

Tiger, which is privately held, said this month that alloClae is experiencing "rapid growth" and the company plans to build a 200-person sales force by the end of 2027 to sell alloClae and a similar product in development, dermaClae, to surgeons, med spas, and other buyers.

When Business Insider spoke to Tiger Aesthetics at the end of last year, the company said it was struggling to keep up with demand. Behind the scenes, it was grappling with more than a shortage.

The company was engaged in a back-and-forth with New York's health department. Between October 2024 and May 2025, the agency sent three letters saying that it could not grant Tiger permission to distribute alloClae in the state.

In July 2025, a health inspector visited two Tiger tissue facilities in Pennsylvania and asked why New York doctors were advertising alloClae. Monica Garcia, the COO of Tiger Aesthetic's parent company, said she was unaware of any shipments to the state and asked what the consequences would be if there were, according to a sworn statement from Joseph Giovannetti, the agency's top investigator.

Garcia, in a sworn statement, said the exchange took place at a Tiger affiliate where employees familiar with alloClae weren't present. She said the inspector didn't ask for follow-up information about alloClae distribution to New York, disputing one of Giovannetti's claims.

Giovannetti said the inspection prompted Tiger to stop shipping alloClae directly to New York and start going through New Jersey and Connecticut.

Despite the letters and inspection, Caroline Van Hove, the president of Tiger Medical Holdings affiliate Tiger Aesthetics, provided reassurances about alloClae to at least one New York plastic surgeon. "We can confirm that the New York Department of Health has not reached out to us in connection with our alloClae product," she wrote in an April 2026 letter seen by Business Insider.

Boxes of alloClae were piled up in a New Jersey driveway

Every week or two, starting no later than September 2025, a new set of white boxes would appear at the clapboard, shuttered home of Robert McGee, a nurse who lived on a cul-de-sac in the central New Jersey town of Tinton Falls, according to FedEx records and a state investigator's statement.

The boxes of alloClae would be stacked next to duffle bags and trash cans in McGee's driveway or on his front porch, according to delivery photos and Giovannetti.

Between September 2025 and April 2026, the company sent over 330 boxes of alloClae to McGee, who loaded them in his pickup, drove them the 50 miles into Manhattan, and dropped them off at more than three dozen plastic surgeons and med spas, Giovannetti said.

McGee did not respond to requests for comment.

In January 2026, the state said in a filing that an unidentified "whistleblower" told regulators what was happening. Three months later, health investigators made an "unannounced inspection" at the office of Dr. Adam Schaffner, a Manhattan plastic surgeon.

Schaffner's paper trail laid out a shift in Tiger's shipping processes. Invoices from July 2025 showed Tiger had sent alloClae directly to his Fifth Avenue office. But starting in August, the month after the inspection, the products were mailed to homes and offices in New Jersey and Connecticut, and employees or Ubers would courier them across state lines, the health department said.

Schaffner, who declined to comment, received at least $95,000 worth of alloClae initially shipped to addresses outside of New York, according to invoices filed in court records.

Some boxes went to the New York City office of plastic surgeon Matthew Schulman, the FedEx records show. In a YouTube video posted last fall, he gleefully unpacked 287.5 cubic centimeters of alloClae as the Pointer Sisters' "I'm So Excited" played in the background. Schulman's name, with McGee's home address, was visible on a shipping label.

If Schulman's boxes were typical — as a review of more than a dozen plastic surgeons' unboxing videos on Instagram suggests — a total of 15,840 cubic centimeters of alloClae could have been sent via McGee's home. The prices on 11 of Schaffner's invoices filed in court average $86.29 per cubic centimeter; at that price, more than $1.3 million worth of alloClae could have been shipped through McGee.

Schulman did not respond to requests for comment.

Tiger has asked that the state's allegations be struck from the court record because, among other things, they argue, the health department could be cherry-picking from its investigative file to benefit their case.

Some New York surgeons are still using alloClae

Doctors who received alloClae say they ordered the product from Tiger and didn't know the route it took.

"He had no idea that this was a challenge, or how stuff was showing up, or any of that," said Ken Sterling, an attorney for Dr. Jason Emer. Sterling said Emer has not been contacted by medical authorities.

Samira Shamoon, a publicist for Dr. Darren Smith, said in an email that "when Dr. Smith was using AlloClae, he purchased it directly from the company and had no knowledge of irregularities." Smith is no longer offering the product, she said.

ME Plastic Surgery, which has locations on Manhattan's Fifth Avenue and in Queens, recently updated a blog post to say that it is not offering alloClae.

Several New York doctors said in early June that they're still using alloClae. Tiger has said it's suspending distribution to New York, but the product can still be "legally sold." In the meantime, doctors in the state continue to promote it.

Emer posted an Instagram video on June 12 showing himself injecting alloClae into a patient's buttocks.

"Don't be left behind," the caption reads, along with a peach emoji. The geotag: New York City.

Inside Meta, employees are facing 28 days of uncertainty before layoffs hit.

• Meta told staff on Thursday that it planned to eliminate 10% of its workforce.
• Inside the company, employees are bracing for weeks of limbo as they wait to find out who will be cut.
• Meta employees responded internally with a mixture of questions, concerns, and jokes.

Welcome to "28 days of hell."

That's how one Meta employee characterized the tech giant's announcement that thousands of jobs will be cut on May 20. Employees flooded internal forums with similar posts, many of which were filled with anxiety, dark humor, and questions as they wait to learn who will be out of a job.

"How are you motivating yourself to work for the next 1 month with layoffs confirmed?" one person posted on the anonymous workplace app Blind, in a section just for Meta employees.

Someone else replied, "I'm motivating myself to do stuff that I can put on my resume for my next job lol."

In a memo sent to staff on Thursday, Meta said it shared some layoff details earlier than usual because the news had already leaked. The company plans to cut around 10% of employees next month and close 6,000 open roles.

"I know this leaves everyone with nearly a month of ambiguity, which is incredibly unsettling," wrote Meta's chief people officer Janelle Gale.

For some Meta employees, the fact that company leadership acknowledged layoffs brought some relief. The layoffs had been so widely discussed internally that the announcement helped ease some uncertainty, according to one employee who declined to be named due to the sensitivity of the matter.

One of the top comments under Gale's internal Meta post was a picture of an elephant, a reference to leadership addressing the elephant in the room. Reuters first reported Meta was planning sweeping layoffs in March, and employees have been speculating on the extent of the cuts in the weeks since.

"elephant addressed!" commented another employee. Another posted a picture of an envelope that read: "Addressed to: "ELEPHANT."

Others said that having to wait almost a month to find out who would be affected created anxiety. One person posted that this was their first week at the company. "It might be goodbye for me," they wrote.

Another employee told Business Insider that the announcement added pressure for them to deliver results over the next month because it's unknown which teams will be affected by the cuts.

"I'm a little stressed about making impact in the next month," they said.

Despite a sense of added pressure, it's not the employee's first go-around with cuts at the company. The worker said they're going to continue working as usual, assuming the worst while trying to make the most of the next month as they wait for further updates.

"I assume I'm always two months away from being laid off, no matter what leadership says, so I'm going to continue to operate as usual," the employee said.

Employees also commented on Gale's internal post with questions.

One person asked if Meta staff would receive their August 15 stock payouts, which are part of some employees' compensation packages. Gale said that impacted employees would have a termination date prior to the August vest and would therefore not receive it.

"Because of the timing of the notifications, we will have just had the May 15 vest. There are some instances, based on work location, where people will remain employed through the August 15 vest," Gale wrote. Another employee thanked Gale for the clarification.

Another employee asked if travel would be restricted the week of May 20. "We are not restricting travel company-wide. VPs will share team-specific guidance," Gale responded.

'I feel more anxious about surviving'

On the Meta employee section of Blind, some users asked why Meta couldn't offer voluntary buyouts. Microsoft on Thursday offered one-time early retirement buyouts to thousands of its long-time employees, and Google has extended the same offers to staff across some orgs.

Many posts were from users asking others for information about which groups might be affected.

In a longer post, one user said the downside might be surviving the cuts.

"I feel more anxious about surviving this layoff," they wrote, recalling several rounds of layoffs at the company since 2022.

"Because we all know it's just gonna get worse for those of us who are left behind and have to absorb even more work, amongst other declining factors in this sad fearful company," they wrote.

• Arm announced its own AI chip, the AGI CPU, and is partnering with OpenAI and Meta.
• The new Arm AGI CPU aims to address energy efficiency and memory constraints in AI data centers.
• Despite strong growth prospects, Arm faces competition from established players like Nvidia and AMD.

Arm has long run its business as an architect behind the scenes, designing chips that power almost all the world's smartphone and making money off royalties from the chips it designs for customers.

Now, Arm is changing it up by announcing its own AI chip, the Arm AGI CPU.

Arm CEO Rene Haas said Tuesday at a company conference that this massive pivot wasn't just an internal strategy shift—it was a direct plea from the world's most powerful AI giants. The company name-dropped OpenAI and Meta as major partners for this chip.

"The biggest reason we're doing this is that our partners have asked for it," Haas said Tuesday.

With energy constraints and memory shortages, the AI boom has created a massive bottleneck in data centers. Faced with this demand, Arm stepped up with an AI chip that it says is more energy-efficient. Arm says it sees a $1.5 trillion market opportunity as it moves into AI chips for cloud, edge, and physical AI.

Arm stock was up by more than 18% on Wednesday. Mizuho analysts wrote that they see "strong growth opportunities" for Arm in AI infrastructure and the automotive industry. Bank of America research analyst Vivek Arya wrote in a note to investors that the company's outlook could be "too ambitious."

Meta and OpenAI partner with Arm

Meta has been building out data centers at a massive scale to power its apps and its latest superintelligence ventures. Santosh Janardhan, head of infrastructure at Meta, said Tuesday onstage that its coming "Hyperion" cluster could draw 5 gigawatts of power, enough to power 50 towns the size of Palo Alto.

"If we met the performance, we couldn't get the power. If we got the power, we wouldn't get the performance," Janardhan said.

This sparked an engineering project within Meta, where engineers were "working 'round the clock" to port its systems to Arm in three months, said Paul Saab, a Meta engineer.

"I didn't even ask my boss here for permission to buy these machines or even start the project," Saab said onstage.

While Saab says he saw major performance benefits, at the time, there wasn't an Arm chip available to buy.

OpenAI faced a similar problem. Its compute demand has grown massively as it trains and runs its ChatGPT models, its AI coding tool Codex, and more.

"That is one of the most common things I hear inside OpenAI. I need more compute," Kevin Weil, vice president of OpenAI for science, said onstage, adding that it needed chips that were energy-efficient.

Arm said it expects this chip to generate $15 billion in revenue by fiscal 2031.

The chip market is 'getting very crowded'

Arm faces the risk that the CPU market is "getting very crowded," Arya wrote in his analyst note. Other competitors, such as AMD, Nvidia, and Intel, have more CPU products and more established customers. Notably, both Meta and OpenAI also work with AMD and Nvidia, which could leave "limited" opportunity for Arm's new CPU, Arya wrote.

"Moreover, the bigger AI grows, the more pressure ARM's smartphone/consumer markets would have from limited memory supplies," Arya wrote.

That said, the increasing demand has led many customers to turn to chip companies beyond Nvidia for their computing needs. Both Meta and OpenAI also work with Broadcom to build AI chips.

The rise of AI agents has also led to greater demand for inference, or how AI models draw conclusions and make predictions. While Nvidia's core AI chips, the GPUs, dominate AI training, CPUs like Arm's AGI CPU can also help with inference. Nvidia also recently made moves into this market.

Have a tip? Contact this reporter via email at rmchan@businessinsider.com, or Signal at rosal.13. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.

• Salesforce is skipping raises for director-level and above employees this year, according to an internal memo.
• The company said it is increasing stock and bonus pools for its "highest performing individuals."
• Employees will find out about their pay during reviews, which start at the end of this month.

Salesforce isn't offering raises this year to employees at the director level and above, according to an internal email viewed by Business Insider.

"We have decided to focus merit increases at the Senior Manager level (grade 8) and below," states the email, sent by the company's human-resources team.

Instead of giving raises, the company said it is increasing stock and bonus pools for its "highest performing individuals" among upper-level employees, calling it part of an "investment in performance and long-term growth."

Employees will learn about their compensation during performance reviews, which begin at the end of March.

Salesforce's decision could reflect a broader shift in how Big Tech is paying senior talent. Instead of increasing base pay, some companies are increasingly tying compensation to stock performance and equity, preserving cash while still incentivizing top leaders. Meta just announced this week that it created a lucrative incentive system for stock for a number of its C-suite executives.

Salesforce stock is down about 37% over the past year. CEO Marc Benioff recently downplayed fears about AI's threat to software-as-a-service companies. Those fears have prompted recent sell-offs of software stocks.

The email stated that 10% more directors and senior directors are getting stock grants, that the average stock grant increased, and that 80% of directors and senior directors who received "highly successful" or "exceptional" performance ratings received a 20% to 40% bigger grant.

The pool for bonuses "is funded at 103%," the email stated. Most eligible directors and senior directors received 100% or more of their bonus, and all of the directors and senior directors who received the top performance ratings got 115% to 140% of their bonuses.

Salesforce laid off some employees around the start of its fiscal year Feb. 1. Those cuts affected fewer than 1,000 employees, according to a person familiar with them. Around that time, the company also hired or promoted six new leaders, replacing five high-profile leaders who had recently announced departures from the company.

Have a tip? Contact this reporter via email at astewart@businessinsider.com or Signal at +1-425-344-8242. Use a personal email address and a nonwork device; here's our guide to sharing information securely.